IL300405A - Methods for treating respiratory diseases characterized by excessive secretion of mucus - Google Patents

Methods for treating respiratory diseases characterized by excessive secretion of mucus

Info

Publication number
IL300405A
IL300405A IL300405A IL30040523A IL300405A IL 300405 A IL300405 A IL 300405A IL 300405 A IL300405 A IL 300405A IL 30040523 A IL30040523 A IL 30040523A IL 300405 A IL300405 A IL 300405A
Authority
IL
Israel
Prior art keywords
semagacestat
gsi
patient
mucus
daily
Prior art date
Application number
IL300405A
Other languages
English (en)
Hebrew (he)
Original Assignee
Univ Leland Stanford Junior
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Leland Stanford Junior filed Critical Univ Leland Stanford Junior
Publication of IL300405A publication Critical patent/IL300405A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/095—Sulfur, selenium, or tellurium compounds, e.g. thiols
    • A61K31/105—Persulfides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4168—1,3-Diazoles having a nitrogen attached in position 2, e.g. clonidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/417—Imidazole-alkylamines, e.g. histamine, phentolamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
IL300405A 2020-08-20 2021-08-19 Methods for treating respiratory diseases characterized by excessive secretion of mucus IL300405A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063068235P 2020-08-20 2020-08-20
PCT/US2021/046742 WO2022040447A2 (en) 2020-08-20 2021-08-19 Methods for treating respiratory diseases characterized by mucus hypersecretion

Publications (1)

Publication Number Publication Date
IL300405A true IL300405A (en) 2023-04-01

Family

ID=80323184

Family Applications (1)

Application Number Title Priority Date Filing Date
IL300405A IL300405A (en) 2020-08-20 2021-08-19 Methods for treating respiratory diseases characterized by excessive secretion of mucus

Country Status (11)

Country Link
US (1) US20230277550A1 (https=)
EP (1) EP4199914A4 (https=)
JP (1) JP2023538125A (https=)
KR (1) KR20230052954A (https=)
CN (1) CN116033895A (https=)
AU (1) AU2021329507A1 (https=)
BR (1) BR112023002651A2 (https=)
CA (1) CA3188234A1 (https=)
IL (1) IL300405A (https=)
MX (1) MX2023001993A (https=)
WO (1) WO2022040447A2 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4268824A1 (en) * 2022-04-26 2023-11-01 Manros Therapeutics Imidazo[2,1-f][1,2,4]triazine derivatives useful as a medicament
WO2024112356A1 (en) * 2022-11-23 2024-05-30 The Board Of Trustees Of The Leland Stanford Junior University Methods for treating respiratory diseases characterized by mucus hypersecretion

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7468365B2 (en) 2000-11-17 2008-12-23 Eli Lilly And Company Lactam compound
SE0101004D0 (sv) 2001-03-21 2001-03-21 Astrazeneca Ab New measuring technique
RS56037B1 (sr) 2004-06-24 2017-09-29 Vertex Pharma Modulatori atp-vezujućih kasetnih transportera
EP3219705B1 (en) 2005-12-28 2020-03-11 Vertex Pharmaceuticals Incorporated Pharmaceutical compositions of the amorphous form of n-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide
CA2644136A1 (en) * 2006-02-27 2007-09-07 The Johns Hopkins University Cancer treatment with gamma-secretase inhibitors
US7645789B2 (en) 2006-04-07 2010-01-12 Vertex Pharmaceuticals Incorporated Indole derivatives as CFTR modulators
EP2674428B1 (en) 2006-04-07 2016-04-06 Vertex Pharmaceuticals Incorporated Modulators of ATP-binding cassette transporters
EP3683218B1 (en) 2007-12-07 2024-09-18 Vertex Pharmaceuticals Incorporated Solid forms of 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl) benzoic acid
US8299059B2 (en) 2009-10-30 2012-10-30 Eli Lilly And Company Crystalline compound and a process for its preparation
PT3030568T (pt) 2013-08-08 2018-12-24 Galapagos Nv Tieno[2,3-c]piranos como moduladores de cftr
EP2932966A1 (en) 2014-04-16 2015-10-21 Novartis AG Gamma secretase inhibitors for treating respiratory diseases
MA41051B1 (fr) 2014-10-06 2020-11-30 Vertex Pharma Modulateurs du régulateur de conductance transmembranaire de la mucoviscidose
US10392378B2 (en) 2014-12-23 2019-08-27 Proteostasis Therapeutics, Inc. Derivatives of 5-phenyl- or 5-heteroarylathiazol-2-carboxylic amide useful for the treatment of inter alia cystic fibrosis
US10548878B2 (en) 2015-07-24 2020-02-04 Proteostasis Therapeutics, Inc. Compounds, compositions, and methods of increasing CFTR activity
BR112018007021B1 (pt) 2015-10-06 2024-01-09 Proteostasis Therapeutics, Inc Composto, composição compreendendo os ditos compostos e uso dos mesmos para tratar fibrose cística
US9890149B2 (en) 2015-10-07 2018-02-13 NuBridge BioSciences Isothiazole derivatives as CFTR modulators
BR112018007161B1 (pt) 2015-10-09 2024-01-16 Galapagos Nv COMPOSTOS PIRAZOLO[3,4-b]PIRIDIN-6-CARBOXAMIDA N-SULFONILADA, COMPOSIÇÃO FARMACÊUTICA CONTENDO OS DITOS COMPOSTOS E USOS DOS MESMOS PARA TRATAR FIBROSE CÍSTICA
AU2017256172A1 (en) 2016-04-26 2018-09-06 AbbVie S.à.r.l. Modulators of cystic fibrosis transmembrane conductance regulator protein
US10138227B2 (en) 2016-06-03 2018-11-27 Abbvie S.Á.R.L. Heteroaryl substituted pyridines and methods of use
TW201811766A (zh) 2016-08-29 2018-04-01 瑞士商諾華公司 N-(吡啶-2-基)吡啶-磺醯胺衍生物及其用於疾病治療之用途
US10399940B2 (en) 2016-10-07 2019-09-03 Abbvie S.Á.R.L. Substituted pyrrolidines and methods of use
MX387203B (es) 2016-11-18 2025-03-18 Cystic Fibrosis Found Pirrolopirimidinas como potenciadores de cftr.
SG10201911076QA (en) 2016-12-16 2020-01-30 Cystic Fibrosis Found Bycyclic heteroaryl derivatives as cftr potentiators
IL268349B2 (en) * 2017-02-17 2024-08-01 Hutchinson Fred Cancer Res Combination therapies for treatment of bcma-related cancers and autoimmune disorders
TW201831471A (zh) 2017-02-24 2018-09-01 盧森堡商艾伯維公司 囊腫纖化症跨膜傳導調節蛋白的調節劑及其使用方法
KR20250030524A (ko) 2019-08-09 2025-03-05 화이자 인코포레이티드 (s)-2-(((s)-6,8-디플루오로-1,2,3,4-테트라하이드로나프탈렌-2-일)아미노)-n-(1-(2-메틸-1-(네오펜틸아미노)프로판-2-일)-1h-이미다졸-4-일)펜탄아미드의고체 상태 형태 및 이의 용도

Also Published As

Publication number Publication date
JP2023538125A (ja) 2023-09-06
EP4199914A2 (en) 2023-06-28
US20230277550A1 (en) 2023-09-07
CN116033895A (zh) 2023-04-28
BR112023002651A2 (pt) 2023-04-04
WO2022040447A3 (en) 2022-04-28
MX2023001993A (es) 2023-02-27
EP4199914A4 (en) 2024-09-04
AU2021329507A1 (en) 2023-03-09
CA3188234A1 (en) 2022-02-24
WO2022040447A9 (en) 2022-06-16
KR20230052954A (ko) 2023-04-20
WO2022040447A2 (en) 2022-02-24

Similar Documents

Publication Publication Date Title
EP4017489B1 (en) Dgd1202 for use in the treatment of kras-mutated cancers
JP6810117B2 (ja) 呼吸器疾患の治療のための方法および製剤
ES2773142T3 (es) Nuevo tratamiento
JP5876435B2 (ja) 骨髄腫の処置のためのｈｄａｃ阻害剤の使用
EA028452B1 (ru) Лечение рака молочной железы
US11219625B2 (en) Inhibitors of N-linked glycosylation and methods using same
US20230277550A1 (en) Methods for Treating Respiratory Diseases Characterized by Mucus Hypersecretion
JP2020536096A (ja) 腫瘍成長を阻害するための材料および方法
JP2026020169A (ja) Ｒｈｏ関連コイルドコイル含有プロテインキナーゼの阻害剤
WO2015195684A2 (en) Small molecule anti-scarring agents
Li et al. Clevudine attenuates bleomycin-induced early pulmonary fibrosis via regulating M2 macrophage polarization
TW202313050A (zh) 組合療法
JP2024533236A (ja) ヒストン脱アセチル化酵素６及び熱ショックタンパク質９０の二重阻害剤
AU2020279003B2 (en) Oxathiazin compounds for inhibiting GAPDH
JP7382660B2 (ja) がん治療用組成物及びその応用、並びに医薬品
CN104271129A (zh) 使用极光激酶抑制剂治疗癌症的方法
WO2024112356A1 (en) Methods for treating respiratory diseases characterized by mucus hypersecretion
US11666643B1 (en) Micronutrient combination to reduce blood pressure
CN101919843B (zh) 羧胺三唑或者羧胺三唑可药用的盐在制备预防和/或治疗矽肺的药物中的用途
CA2808866A1 (en) Compositions and methods for treatment of cystic fibrosis and diseases associated with aberrant protein cellular processing
CA2907921C (en) Inhibition of il-2 production
JP7201400B2 (ja) Ｅｚｈ２阻害剤組合せ療法
JP2009515862A (ja) 増殖症の治療のためのロスコビチンとｈｄａｃ阻害剤との組合せ
JP2009504674A (ja) 有機化合物の組合せ
WO2023022198A1 (ja) 新型コロナウイルス感染症関連疾患の新規な予防又は治療剤